Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm Group Co. Ltd. has announced that its board of directors will hold a meeting on October 24, 2025, to consider and approve the unaudited quarterly results for the nine months ending September 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (HK:1099) stock is a Hold with a HK$20.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. It focuses on the distribution and retail of pharmaceutical and healthcare products, playing a significant role in the healthcare market.
Average Trading Volume: 5,661,633
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.35B
See more data about 1099 stock on TipRanks’ Stock Analysis page.